1. Home
  2. USEA vs CALC Comparison

USEA vs CALC Comparison

Compare USEA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Maritime Corporation

USEA

United Maritime Corporation

HOLD

Current Price

$2.76

Market Cap

21.7M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.46

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USEA
CALC
Founded
2004
2011
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
19.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
USEA
CALC
Price
$2.76
$0.46
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
53.3K
353.4K
Earning Date
05-21-2026
05-13-2026
Dividend Yield
11.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.55
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.46
52 Week High
$2.91
$7.20

Technical Indicators

Market Signals
Indicator
USEA
CALC
Relative Strength Index (RSI) 58.05 33.03
Support Level $2.65 N/A
Resistance Level $2.78 $0.73
Average True Range (ATR) 0.12 0.05
MACD 0.00 -0.01
Stochastic Oscillator 55.65 3.93

Price Performance

Historical Comparison
USEA
CALC

About USEA United Maritime Corporation

United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: